ICU Medical (ICUI) Q4 2017 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2017 earnings summary
6 Nov, 2026Executive summary
2017 marked the February acquisition of Hospira Infusion Systems (HIS), transforming the portfolio into a broad infusion-therapy offering spanning consumables, IV solutions, pumps and critical care.
Integration advanced through commercial-team consolidation, capacity adjustments and positive FDA inspections at acquired facilities; 2018 was expected to bring execution challenges as Pfizer transition services expired.
Financial highlights
FY2017 revenue was $1,292.6M and net income was $68.6M; operating loss was $15.1M, including $78.0M of restructuring and strategic transaction expenses.
Diluted EPS was $3.29 vs. $3.66 in 2016; FY2017 included a $70.9M HIS bargain-purchase gain and a $20.8M tax benefit from excess stock-compensation tax benefits.
Q4 revenue was $370.1M, gross profit $137.5M, net income $49.7M and diluted EPS $2.33.
Operating cash flow was $154.4M; cash, cash equivalents and short-term investments totaled $300.1M at year-end, down $144.9M, primarily due to acquisitions and integration costs.
Outlook and guidance
2018 priorities centered on completing HIS integration and Pfizer carve-out activities; management cautioned that execution demands could reduce predictability.
FY2018 capital expenditures were estimated at $80M–$90M for manufacturing equipment, customer-placed infusion products and global IT; actual spending could differ substantially.
Management expected available cash and future operating cash flows to fund operations for the next 12 months; focus remained on customer service, innovation and free-cash-flow generation.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020